BIOTECHNOLOGY. This Patent and Technology License Agreement (“Agreement”) is between The Board of Regents (“Board”) of The University of Texas System (“System”), an agency of the State of Texas whose address is 200 Xxxx 0xx Xxxxxx, Xxxxxx, Xxxxx 00000 on behalf of The University of Texas Southwestern Medical Center (“UT Southwestern”), a component institution of System, whose address is 5000 Xxxxx Xxxxx Boulevard, Dallas, Texas 75390-9094 (“Licensor”) and MAIA Biotechnology, Inc., a Delaware corporation, with its principal place of business at 400 Xxxx Xxxx Xxxxxx, Xxxxx 0000, Xxxxxxx, XX 00000 (“Licensee”) (collectively, “Parties”, or singly, “Party”). This Agreement has an “Effective Date” of the date of the last signature hereto. No binding agreement between the Parties will exist until the Agreement has been signed by both Parties. Unsigned drafts of the Agreement shall not be considered offers. Background Licensor and Licensee have previously entered into “Patent & Technology License Agreement Agt. No. L2664-MAIA Biotechnology,” as amended, which was executed December 8, 2020. This agreement and all of its exhibits and schedules and including any and all amendments to any of the foregoing will be referred to collectively in this agreement as the “Original Agreement.” As set forth in the Original Agreement, Licensee had the option to obtain additional licenses to technology developed by the Licensor. The instant Agreement between the Licensor and Licensee is directed to granting Licensee such additional license rights. In that regard, Licensor owns or controls Licensed Subject Matter (defined below). Licensee desires to secure the right and license to use, develop, manufacture, market, and commercialize the Licensed Subject Matter. Licensor has determined that such use, development, and commercialization of the Licensed Subject Matter is in the public’s best interest and is consistent with Licensor’s educational and research missions and goals. Licensor desires to have the Licensed Subject Matter developed and used for the benefit of Licensee, the inventors, Licensor, and the public.
BIOTECHNOLOGY. This Patent and Technology License Agreement (“Agreement”) is between The Board of Regents (“Board”) of The University of Texas System (“System”), an agency of the State of Texas whose address is 200 Xxxx 0xx Xxxxxx, Xxxxxx, Xxxxx 00000 on behalf of The University of Texas Southwestern Medical Center (“UT Southwestern”), a component institution of System, whose address is 5000 Xxxxx Xxxxx Boulevard, Dallas, Texas 75390-9094 (“Licensor”) and MAIA Biotechnology, Inc., a Delaware corporation, with its principal place of business at 400 Xxxx Xxxx Xxxxxx, Xxxxx 0000, Xxxxxxx, XX 00000 (“Licensee”) (collectively, “Parties”, or singly, “Party”). This Agreement has an “Effective Date” of the date of the last signature hereto. No binding agreement between the Parties will exist until the Agreement has been signed by both Parties. Unsigned drafts of the Agreement shall not be considered offers.
BIOTECHNOLOGY l. Biotechnology for agriculture, aquaculture, forestry and biomass production;
BIOTECHNOLOGY. (a) The Parties appreciate that marine environment is a source of unique chemical compounds with vast potential for industrial and commercial development as pharmaceuticals, cosmetics, nutritional supplements, molecular probes, enzymes, fine chemicals and agrichemicals.
BIOTECHNOLOGY. TAGs may be written in Biotechnology for students who meet the TAG criteria for the College of Agricultural and Environmental Sciences [Section III)A)1)] and who meet the following additional criteria: Mathematics 16A/B or Mathematics 17A/B or Mathematics 21A/B Students must have a GPA of at least 2.50 for this group of courses. Courses must be taken for a letter grade, with no grade less than "C." Chemistry 2A/B/C Students must have a GPA of at least 2.50 for this group of courses. Courses must be taken for a letter grade, with no grade less than "C." Biological Sciences 1A or 1B or 1C OR Biological Sciences 2A or 2B or 2C (Series completion highly recommended) o A minimum of one course equivalent to a UC Xxxxx Biological Sciences course must be competed with a "B" grade or higher for admission. o If two courses or the entire series are completed, a group GPA of 2.50 or higher is required. Courses must be taken for a letter grade, with no grade less than "C." We strongly encourage students to complete an entire biological sciences series, either Biological Sciences 1A/B/C or Biological Sciences 2A/B/C before matriculating to UC Xxxxx. Students may wish to consider completing the series during summer session at their current school or at UC Xxxxx before enrolling for the fall term as this will allow for a smoother transition and reduce time to degree. It is strongly recommended that students complete courses comparable to the following UC Xxxxx courses with a GPA of at least 2.50 for the group. Completion of these courses will help the student move more efficiently toward graduation. Courses should be taken for a letter grade, with no grade less than "C": Organic Chemistry 8A/B or 118A/B/C
BIOTECHNOLOGY. The low cost of natural gas and biogas compared to other fuels makes them promising feedstocks for bioconversions. Possible bioproducts include polymers, single-cell protein, vitamins, carotenoids, compatible solutes, lipids, or methanol (Strong et al. 2015). As of yet, there are no published reports of the use of verrucomicrobial methanotrophs for bioconversion or indeed for any other biotech- nological use. At the moment one can only speculate that their unique biochemistry compared to all other methanotrophs may present unique possibilities for bioproduct discovery and production. Ecologically, the Verrucomicrobia methanotrophs occupy a niche separate from proteobacterial methanotrophs and may therefore also present unique possibilities for environmental biotechnology. For example, biofiltration of methane is a useful way of reducing the carbon footprint of waste gas streams that are economically not feasible to recover because they are intermittent, remote, and contaminated or have low flow rates or low methane contents (Hettiarachchi and Hettiaratchi 2011). Via biofiltration, the potent greenhouse gas methane is oxidized to CO2, a gas with a global warming potential 34 times less than methane. The presence of H2S in biogas or natural gas (“sour gas”) is a general problem for the sustained operation of a methane biofilter and in some situations is also problematic for the economic recovery of fuel methane. The Verrucomicrobia methanotrophs are naturally adapted to sour gas sources and may therefore be useful in biofiltration of sour gas. Their unique tolerance may even make sour gas streams viable feedstocks for biotechnol- ogy without a desulfurization step. The observed co-occurrence of sulfur- and methane-oxidizing acidophiles in soured pipes (Pagaling et al. 2014) indicates the possibility for simultaneous H2S and CH4 removal from waste gas. References Xxxxx XX, Xxxxx X, Xxx A et al (2014) The genomic landscape of the verrucomicrobial methano- troph Methylacidiphilum fumariolicum SolV. BMC Genomics 15:914 Xxxxxx A, Xxxxx D, xx Xxxxx R et al (2015) A metagenomics-based metabolic model of nitrate- dependent anaerobic oxidation of methane by Methanoperedens-like archaea. Front Microbiol 6:1423 Xxxxx M, Xxxxxxx W (2008) Two isozymes of particulate methane monooxygenase with different methane oxidation kinetics are found in Methylocystis sp. strain SCZ. Proc Natl Acad Sci USA 105:10203–10208 Xxxx XX, House CH, Orphan VJ (2009) Manganese- and iron-dependent m...
BIOTECHNOLOGY. Any technique that uses living organisms or sub- stances from those organisms to make or modify a product, to improve plants or animals, or to devel- op microorganisms for specific uses. These tech- niques include the use of novel DNA, cell fusion, and other bioprocesses. Cooperative Research and Development Agreement (CRADA) A formal agreement between a federal laboratory and a nonfederal party (individual, university, or private firm) in which the nonfederal party pro- vides resources in exchange for exclusive rights to license patents that result from collaboration. Congress gave federal laboratories the authority to enter into CRADAs as part of the Federal Technology Transfer Act of 1986 (Public Law 99-502). Deoxyribonucleic acid (DNA) The molecule that encodes genetic information. DNA is a double-stranded helix held together by weak bonds between base pairs of nucleotides. DNA See deoxyribonucleic acid.
BIOTECHNOLOGY. Biohydrometallurgy is a branch of extractive metallurgy which describes biotechnological processes that involve interactions between microorganisms and metal-bearing minerals. Bioleaching and bioremediation are two of the most studied branches in this field and are employed worldwide at commercial scale. Bioleaching involves the use of naturally occurring microorganisms to recover gold, base metals and uranium from mineral ores, concentrates and a range of waste materials. Mintek has established an internationally recognised position for the treatment of sulphide ores and concentrates bearing gold and base metals. The tank bioleaching technologies developed by Mintek typically find application in niche areas for treatment of refractory gold concentrates as well as complex polymetallic concentrates which contain impurities that attract smelting penalties. The organisation has the ability to take processes from amenability test work through to piloting, flowsheet design, techno-economic studies and commercial implementation. With the depletion of higher grade resources, Mintek’s biotechnology processes have shifted focus to include heap xxxxx applications where metals are extracted into solution from minerals contained in dumps or stacked heaps of low- grade ores. The learnings from biological heap leaching have been expanded to also include acid, alkaline and chloride heap leaching in the division’s portfolio. In addition, Mintek has the unique ability to combine percolation xxxxx test work with geomechanical (hydraulic / hydrodynamic) testing of such ores and their xxxxx residues. This allows Mintek to offer clients a combination of metallurgical performance results and geomechanical/hydrodynamic information from which engineering can be done based on quantified specifications provided. Mintek’s activities in this area range from a suite of various bench-scale tests to integrated pilot and demonstration tests at Pre-Feasibility Study or Process Selection Phase level, enabling commercial clients to determine ideal flowsheet design and operating conditions for optimizing value. There is a global trend to move the mining industry towards participating in a circular economy by promoting and investing in sustainable solutions and green technologies. Mintek is uniquely positioned to contribute to this drive through its multi-disciplinary capabilities, which include bioprocessing, chemical and environmental engineering and biological sciences expertise. The focus...
BIOTECHNOLOGY. Mintek’s Biotechnology programme is a branch of extractive metallurgy which describes biotechnological processes that involve interactions between microorganisms and metal-bearing minerals. Bioleaching and bioremediation are two of the most studied branches in this field and are employed worldwide at commercial scale. Bioleaching involves the use of naturally occurring microorganisms to recover gold, base metals and uranium from mineral ores, concentrates and a range of waste materials. The programme is a well-established programme of Mintek that is internationally recognised for the treatment of sulphide ores and concentrates bearing gold and base metals. The objectives that will be pursued over the next financial year are outlined below.
BIOTECHNOLOGY. We see a great opportunity for Germany to increase its competitiveness as a centre of business and science in biotechnological research, development and application. We will continue to develop the potential of responsible innovations in biotechnology and genetic engineering to secure Germany’s position as a business centre and to meet our global responsibilities. We will work together with the Bioeconomy Council to draft and implement an internationally competitive strategy for a knowledge-based bioeconomy. The scientific, business and agricultural communities require clear signals regarding research into and the use of genetically modified plants based on current law. Green genetic engineering can contribute to the fight against global famine. Health research Prevention is better than cure. We will strengthen prevention research. New findings produced by research must benefit people more quickly. We are paving the way for individualised medicine and therapies that are more effective and better tolerated by patients. This must be accompanied by new concepts in health system and health care research. With “German Centres for Health Research” that bring together research institutions, universities, university clinics and clinics in equal and long-term partnership we will create the necessary conditions for combating the rapid increase in common diseases. Stem cell research Stem cell research offers great opportunities for the health sector. We want to ensure that these opportunities can be realised in Germany. At the same time, ethically sensitive research must take place within the framework of current law and involve all the key players in society. We are investigating the establishment of a platform for dialogue called the “German Stem Cell Network”. Page 77
